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NK cell–derived GM-CSF potentiates inflammatory
arthritis and is negatively regulated by CIS
Cynthia Louis1,2*, Fernando Souza-Fonseca-Guimaraes2,3,4*, Yuyan Yang1,2, Damian D’Silva1,2, Tobias Kratina2,3, Laura Dagley2,5,
Soroor Hediyeh-Zadeh2,6, Jai Rautela2,3,7, Seth Lucian Masters1,2, Melissa J. Davis2,6, Jeffrey J. Babon2,8, Bogoljub Ciric9, Eric Vivier10,11,12,
Warren S. Alexander2,13, Nicholas D. Huntington2,7**, and Ian P. Wicks1,2,14**
Despite increasing recognition of the importance of GM-CSF in autoimmune disease, it remains unclear how GM-CSF is
regulated at sites of tissue inflammation. Using GM-CSF fate reporter mice, we show that synovial NK cells produce GM-CSF in
autoantibody-mediated inflammatory arthritis. Synovial NK cells promote a neutrophilic inflammatory cell infiltrate, and
persistent arthritis, via GM-CSF production, as deletion of NK cells, or specific ablation of GM-CSF production in NK cells,
abrogated disease. Synovial NK cell production of GM-CSF is IL-18–dependent. Furthermore, we show that cytokine-inducible
SH2-containing protein (CIS) is crucial in limiting GM-CSF signaling not only during inflammatory arthritis but also in
experimental allergic encephalomyelitis (EAE), a murine model of multiple sclerosis. Thus, a cellular cascade of synovial
macrophages, NK cells, and neutrophils mediates persistent joint inflammation via production of IL-18 and GM-CSF. Endogenous
CIS provides a key brake on signaling through the GM-CSF receptor. These findings shed new light on GM-CSF biology in
sterile tissue inflammation and identify several potential therapeutic targets.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that targets synovial joints. The pathology of RA includes the
generation of autoantibodies and persistent cytokine dysregu-
lation. It has become clear that the cytokine GM-CSF (CSF2)
plays an important role in RA as well as other autoimmune
diseases (Becher et al., 2016; Wicks and Roberts, 2016). GM-
CSF–deficient mice have attenuated collagen-induced arthritis
(CIA, a murine model of RA) and experimental autoimmune
encephalomyelitis (EAE, a murine model for multiple sclerosis
[MS]; Campbell et al., 1998; McQualter et al., 2001). Recent
clinical trials confirm the benefit of GM-CSF antagonism on
established disease in RA (Burmester et al., 2017, 2018). How-
ever, how GM-CSF is regulated at sites of tissue inflammation is
not well understood.
GM-CSF can be produced by a number of cell types, de-
pending on the inflammatory context. GM-CSF–producing
T helper (Th) type 17 cells have been identified in the arthritic
joints of autoimmune SKG mice, a strain that carries a point
mutation in the gene encoding the TCR-proximal signaling
molecule ZAP-70 (Hirota et al., 2018). Synovial fibroblasts and
type 2 innate lymphoid cells (ILC) were also identified as GM-
CSF producers, induced by IL-17 or damage-associatedmolecular
patterns, respectively (Hirota et al., 2018). In the EAE model of
MS, GM-CSF confers pathogenicity on the CD4+ Th17 cell subset
(Codarri et al., 2011; El-Behi et al., 2011; Komuczki et al., 2019),
which in turn primes an encephalitogenic phenotype in Ly6C+
monocytes (Croxford et al., 2015). GM-CSF–producing CD4+
T cells have been identified in cerebrospinal fluid of MS patients
(Noster et al., 2014) and in the synovium of RA patients
(Reynolds et al., 2016). However, GM-CSF production is not
restricted to these cells. Other sources include innate response
activator B cells during sepsis (Rauch et al., 2012), cardiac
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fibroblasts in myocardial infarction and coronary vasculitis
(Anzai et al., 2017; Stock et al., 2016), and natural killer (NK)
cells during systemic Candida albicans infection (Bär et al., 2014;
Domı́nguez-Andrés et al., 2017). Thus, GM-CSF can be produced
by hematopoietic and/or nonhematopoietic cells, depending on
the inflammatory context and environmental triggers.
RA is associated with a number of autoantibodies (e.g., anti-
cyclic citrullinated peptide antibodies, rheumatoid factor), and
these predict more severe disease (Smolen et al., 2016; Syversen
et al., 2008). The serum transfer-induced arthritis (STIA) model
has been widely used to study the effector phase of autoantibody-
mediated arthritis (Korganow et al., 1999; Monach et al., 2008).
GM-CSF contributes to STIA independently of adaptive immune
cells (Cook et al., 2011). However, how GM-CSF is regulated in this
clinically relevant context remains to be defined. Neutrophils and
macrophages are the major cells in the inflammatory infiltrate in
the STIA model (Ji et al., 2002a), but other innate immune cells,
such as mast cells and NK cells, have also been reported (Nigrovic
and Lee, 2007; Söderström et al., 2010). Little is known about
whether, and how, these accessory cells impact on the course of
joint inflammation.
NK cells are a subset of ILCs, with antitumoral and antiviral
functions (Vivier et al., 2011; Vivier et al., 2018). NK cells have
been hypothesized to promote antibody-mediated autoimmu-
nity through engagement of FcγRIIIa/CD16, as well as their
natural cytotoxicity receptors (NCR), and to activate myeloid
cells via cytokine production (Schleinitz et al., 2010). NK-
derived IFN-γ has been linked to more severe RA (Dalbeth and
Callan, 2002; Pridgeon et al., 2003; Yamin et al., 2019), but the
role of IFN-γ and NK cells in experimental models of arthritis
remains controversial. IFN-γ−/−mice developedmore severe CIA
(Guedez et al., 2001), and there are conflicting reports on the
effect of NK cell depletion in the CIA model (Lo et al., 2008;
Söderström et al., 2010). Thus, although it is known that im-
mature, noncytotoxic, cytokine-producing NK cells are present
in the inflamed synovium of arthritis patients (Dalbeth and
Callan, 2002; Pridgeon et al., 2003; Yamin et al., 2019),
whether and how these synovial NK cells contribute to the
course of arthritis remain to be investigated.
GM-CSF signaling primes myeloid cells for developmental
and pro-inflammatory functions. GM-CSF signaling is mediated
through the heterodimeric GM-CSF receptor (GM-CSFRα, a
specific, low-affinity ligand-binding subunit) and the common
signaling β (GM-CSFRβ) signal-transducing subunit, which is
shared with the IL-3 and IL-5 receptors. The suppressor of
cytokine signaling (SOCS) proteins (cytokine-inducible SH2-
containing protein [CIS], SOCS1-7) are cytokine-inducible neg-
ative regulators that limit cytokine signaling. SOCS family
proteins possess a central SH2 domain (which binds to phos-
phorylated tyrosine motifs in target proteins) and a C-terminal
SOCS box that mediates the formation of an E3 ubiquitin ligase
complex to ubiquitinate SOCS-interacting proteins for protea-
somal degradation (Morris et al., 2018). Although a number of
SOCS family members have been proposed (Bunda et al., 2013;
Esashi et al., 2008; Jackson et al., 2004), whether GM-CSF sig-
naling induces direct, stimulus-induced negative regulation has
not been resolved (Wicks and Roberts, 2016).
In this report, we addressed two related aspects of GM-CSF
biology in the context of autoantibody-mediated inflammatory
arthritis. Using gene reporter mice, we identified NK cells as a
major cellular source of GM-CSF production in STIA. We found
that mice with genetic or pharmacologic depletion of NK cells
still developed arthritis, but had markedly reduced disease
progression. To address if NK-derived GM-CSF contributes to
STIA, we generated a Csf2fl/fl transgenic mouse line to allow
specific GM-CSF deletion. Deletion of GM-CSF in NK cells was
sufficient to suppress the progression of STIA. We also found
that GM-CSF production by synovial NK cells was regulated by
IL-18. Furthermore, we validated CIS as a key suppressor of GM-
CSF signaling. Loss of CIS resulted in prolonged GM-CSF–driven
JAK-STAT signaling in myeloid cells, and in keeping with these
observations, CIS-deficient mice had exacerbated STIA. We
provide evidence for altered recycling of GM-CSFRβ in the ab-
sence of CIS. In summary, synovial NK cells can propagate
antibody-mediated joint inflammation via GM-CSF production,
following activation by IL-18. We show that the SOCS family
member CIS is a direct, stimulus-induced negative regulator of
GM-CSF signaling in myeloid cells. These findings shed new
light on how GM-CSF mediates autoimmune tissue inflamma-
tion and reveal several new potential therapeutic targets.
Results
GM-CSF is produced by NK cells during
autoantibody-mediated arthritis
GM-CSF production is required for CIA (Campbell et al., 1998)
and STIA (Cook et al., 2011). Previous studies have highlighted
the production of GM-CSF by diverse cell types, including CD4+
Th17 cells, tissue fibroblasts, and most recently, type 2 ILCs
(Anzai et al., 2017; Hirota et al., 2018; Stock et al., 2016). It is
unknown which cells produce this pro-inflammatory cytokine
during T cell–independent, autoantibody-mediated STIA. We
used a GM-CSF reporter/fate reporter (Gr/fr) mouse system
(Fig. S1 A) to monitor GM-CSF expression at the single-cell level.
Briefly, this transgenic construct reports expression of GM-CSF,
driven by the physiological control elements for the Csf2 gene.
GM-CSF expression triggers expression of both iCre and blue
fluorescent protein (BFP). These mice were crossed to Ro-
sa26eYFP mice to generate Gr/fr mice that also enable lineage
tracing via iCre-mediated YFP expression. Hence, cells ex-
pressing GM-CSF in real time can be identified as BFP+ YFP+,
while BFP– YFP+ marked cells have ceased to express GM-CSF.
To validate this system, we verified a BFP+ YFP+ population in
Th17-polarized splenocytes (Fig. S1 B). Furthermore, a CD45–
BFP+ YFP+ population was identified in the lung, most likely
representing gp38– epithelial cells and gp38+ fibroblasts (Fig. S1 C),
which are known producers of GM-CSF in the normal lung
(Guilliams et al., 2013).
Unlike WT mice, the GM-CSF–producing BFP+ YFP+ popula-
tion was readily apparent in the joints of Gr/fr mice with STIA
(Fig. 1 A), which were distinct from autofluorescent (YFP–)
synovial exudate cells observed in both WT and Gr/fr mice. The
frequency of GM-CSF–producing BFP+ cells in the synovium
paralleled the clinical progression of STIA, which increases up to
Louis et al. Journal of Experimental Medicine 2 of 19
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day 10 and resolves spontaneously by day 16 (Fig. 1 B). The
majority of exudate cells in the STIA joints were Ly6G+ neu-
trophils and CD64+ macrophages (Fig. 1 C). Neutrophils and
macrophages were highly autofluorescent, but were BFP– YFP–
(Fig. 1 C). In contrast, YFP+ cells were identified in the non-
myeloid (Ly6G– CD64–), Lin– (TCRβ, CD3ε, CD19) fraction, and
BFP+ cells were evident in the CD49b+NK1.1+ NK cell gate (Fig. 1 C).
As shown in Fig. 1 D, almost all BFP+ cells were mature NK cells
(CD127– NKp46+ CD49b+), while other cells with a history of
producing GM-CSF (BFP– YFP+) were primarily other ILC
subsets (CD127+ NKp46+ CD49b–). BFP– YFP+ CD127– non-ILCs
comprised the remaining fraction of CD49b+ NKp46+ NK cells
(Fig. 1 D). Of note, BFP+ cells were mainly found in the viable
CD45+ gate, indicating nonhematopoietic cells are minimal
contributors to GM-CSF production in STIA (Fig. S1 D). These
results demonstrate that NK cells are recruited to inflamed
joints and produce GM-CSF during STIA.
To corroborate our findings from the mouse system, we an-
alyzed synovial fluid (SF) cells from RA patients with high levels
of anti–cyclic citrullinated peptide antibodies, and peripheral
Figure 1. NK cells produce GM-CSF in STIA. (A) Repre-
sentative FACS plots showing GM-CSF–producing cells
(BFP+YFP+) in the inflamed joints of WT or Gr/fr mice with
STIA. (B) Proportion of GM-CSF-producing (BFP+) cells
among GM-CSF producers (total YFP+) cells in the STIA in-
flamed joints of Gr/fr mice across various time points
of arthritis. Vertical bars, mean ± SEM, n = 3–5 mice.
(C) Representative FACS plots showing gating strategies
used to identify GM-CSF–producing cells (BFP+YFP+) among
joint-infiltrating immune cells in the Gr/fr mice with STIA.
Data shown for A–C are representative of two independent
experiments. (D) Representative FACS plots showing seg-
regation of GM-CSF–producing cells (BFP+YFP+) and other
cells with a history of producing GM-CSF (BFP– YFP+) in Gr/fr
mice with STIA. FSC-A, forward scatter area; SSC-A, side
scatter area.
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blood cells from healthy donors as controls. As reported previ-
ously (Dalbeth and Callan, 2002; Yamin et al., 2019), SF-
infiltrating NK cells were mainly immature CD56bright cells,
which is a potent cytokine-producing subset (Caligiuri, 2008), in
contrast to the mostly mature CD56dim cytotoxic subset found in
the peripheral blood of healthy donors (Fig. S2, A to B). Because
CD4+ T cells are known to be GM-CSF producers (Reynolds et al.,
2016), we also examined the composition of the GM-CSF–, or
GM-CSF/IFN-γ–expressing T and NK cell compartment from SF
samples from three RA patients (Fig. S2 C). As expected, CD4
T cells from RA patients produced GM-CSF, or GM-CSF and IFN-γ,
at higher frequencies than other T cells (such as CD8 T cells),
as shown by intracellular staining (Fig. S2, C–E). However,
synovial NK cells also constituted a significant proportion of
GM-CSF–producing cells (Fig. S2 D). These data confirm that
CD4 Th cells are a major source of GM-CSF, but reveal that NK
cells can also contribute to the production of GM-CSF in RA.
NK cells contribute to the maintenance of
autoantibody-induced arthritis
To determine if NK cells directly contribute to the pathogenesis
of STIA, we examined disease development in Mcl1fl/fl:Ncr1-Cre
NK-deficient mice (Sathe et al., 2014) and anti-NK1.1–treated NK
depleted mice. The onset of STIA was comparable in NK-
deficient mice relative to NK-sufficient mice, but there was
consistently reduced disease severity at later time points (Fig. 2,
A and B). Flow-cytometric analysis confirmed reduction in the
numbers of NK cells, neutrophils, and macrophages in the joints
of bothMcl1fl/fl:Ncr1-Cre and anti-NK1.1–treatedWTmice (Fig. 2,
A and B), relative to control mice.
To ascertain whether cytokine-production by NK cells is
functionally important in STIA, we induced STIA in CD45−/−
mice. CD45−/− mice have an expanded NK compartment and
intact cytolytic capacity, but are unable to produce cytokines
following stimulation of Fc receptors, due to impaired signal
transduction (Hesslein et al., 2006; Huntington et al., 2005).
Similar to NK-deficient mice, CD45−/− mice had equivalent dis-
ease onset, but lower arthritis severity at later time points (Fig. 2
C). CD45−/− mice had an intact synovial NK cell population, but
still developed less neutrophil and macrophage infiltration of
inflamed joints (Fig. 2 C). These data suggest that the cytokine-
producing function of NK cells, rather than NK cell cytotoxicity,
promotes STIA.
Following our observation that NK cells produce GM-CSF
during STIA (Fig. 1 C) and because NK cells are well-known
producers of IFN-γ during inflammation, we compared STIA
in GM-CSF−/− and IFN-γ−/− mice to determine the relative con-
tributions of these inflammatory cytokines. GM-CSF−/− but not
IFN-γ−/− mice had reduced arthritis severity (Fig. 2, D and E),
highlighting a pathogenic role for GM-CSF rather than IFN-γ in
promoting STIA. Neither GM-CSF nor IFN-γ deficiency affected
the numbers of joint NK cells, but GM-CSF−/−mice had less joint-
infiltrating neutrophils and macrophages (Fig. 2, D and E),
paralleling reduced arthritis severity. Taken together, these
results show that NK cells promote autoantibody-induced
inflammatory arthritis through GM-CSF, rather than IFN-γ,
production.
GM-CSF production by NK cells promotes the persistence of
autoantibody-induced arthritis
To control GM-CSF expression in vivo, we generated Csf2fl/fl
mice (Fig. 3 A). We then generated Csf2fl/fl:Ncr1-Cre mice to
delete GM-CSF production specifically in NK cells. We con-
firmed that GM-CSF, but not IFN-γ, production was specifically
depleted in splenic NK cells of Csf2fl/fl:Ncr1-Cre mice following
in vitro stimulation with IL-15 and IL-18 (Fig. 3 B). Importantly,
Csf2fl/fl:Ncr1-Cre mice (Fig. 3 C) recapitulated the reduced STIA
of NK- or GM-CSF–deficient mice (Fig. 2, A, B, and D), including
reduced numbers of synovial neutrophils and macrophages, but
not synovial NK cells (Fig. 3 C). Intracellular GM-CSF staining
confirmed GM-CSF deletion in synovial NK cells from arthritic
Csf2fl/fl:Ncr1-Cre mice relative to Csf2fl/fl mice (Fig. 3 D). To de-
termine the effect of NK cell–derived GM-CSF in another model
of inflammatory arthritis, we examined CIA, which is also de-
pendent on autoantibodies generated following immunization to
type II collagen (Svensson et al., 1998). Again, we found no
difference in the onset of CIA, but a reduction in the progression
and severity of inflammatory arthritis in the Csf2fl/fl:Ncr1-Cre
mice (Fig. 3 E). These results demonstrate that NK cells con-
tribute to the persistence of autoantibody-induced inflamma-
tory arthritis via GM-CSF production.
IL-18 controls GM-CSF production by synovial NK cells
IL-18 can induce GM-CSF production by NK cells in vitro (Brady
et al., 2010; Fig. 3 B), and IL-18 has been shown to be produced by
synovial macrophages from RA, but not osteoarthritis, patients
(Gracie et al., 1999). Joint lavage from WT STIA mice showed
elevated IL-18 (Fig. 4 A). We therefore assessed the relevance of
IL-18 to GM-CSF production by NK cells in STIA. IL-18−/− mice
had reduced STIA (Fig. 4 B) and less synovium-infiltrating my-
eloid cells (Fig. 4 C). While the number of joint NK cells in IL-
18−/− mice was comparable to WT mice (Fig. 4 C), intracellular
GM-CSF staining confirmed a reduced frequency of GM-
CSF–producing synovial NK cells (Fig. 4 D). Consistent with
reduced GM-CSF production, levels of secreted GM-CSF and
CCL17 were also lower in the joint lavages of IL-18−/− mice (Fig. 4
E). Taken together, these findings show that IL-18 augments
GM-CSF production by synovial NK cells in STIA.
GM-CSF induces CIS to limit JAK2-STAT5 signaling in myeloid
cells
Our understanding of how GM-CSF signaling is regulated re-
mains incomplete (Becher et al., 2016; Wicks and Roberts, 2016).
Many cytokines induce SOCS proteins to negatively regulate
signaling via inhibition of STAT binding to the receptor com-
plex, or proteasome-mediated degradation of signaling compo-
nents (Morris et al., 2018). To explore mechanisms regulating
GM-CSF signaling, we profiled GM-CSF–induced SOCS expres-
sion in purified mouse bone marrow (BM) neutrophils. GM-CSF
induced Cish and Socs3 mRNA within 2 h of GM-CSF treatment,
but only Cish mRNA levels were sustained at later time points,
and these were more prominent than Socs3 mRNA (Fig. 5 A). In
contrast, granulocyte-colony stimulating factor (G-CSF) mod-
estly induced a transient up-regulation of Socs3 mRNA in neu-
trophils (Fig. 5 A), consistent with SOCS3 being the inducible
Louis et al. Journal of Experimental Medicine 4 of 19
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negative regulator of G-CSF signaling (Croker et al., 2004). CIS
induction and STAT5 phosphorylation following GM-CSF stim-
ulation also occurred in human neutrophils and monocytes (Fig.
S3 A).
Given consistent CIS induction following GM-CSF stimula-
tion in GM-CSFR–expressing primary myeloid cells (Fig. 5 A and
Fig. S3 A), we hypothesized that CIS acts as a molecular brake on
GM-CSF signaling. We therefore examined GM-CSF–induced
activation of the JAK-STAT pathway in CIS-deficient mice
(Delconte et al., 2016; Palmer et al., 2015). Steady-state numbers
of myeloid cells (neutrophils, monocytes, conventional dendritic
cells, and macrophages) in BM, blood, spleen, and peritoneal
cavity were comparable in CIS−/− mice compared with WT mice
(Fig. S3 B). The normal myeloid compartment of CIS−/− mice is
consistent with GM-CSF not playing a role in steady-state mye-
lopoiesis (i.e., apart from the lung; Stanley et al., 1994). Freshly
isolated WT or CIS−/− neutrophils lack JAK2-STAT5 activation
(Fig. 5 B), consistent with negligible GM-CSF production in the
steady-state (Wicks and Roberts, 2016). Following GM-CSF
stimulation, CIS−/− neutrophils had similar phosphorylation ki-
netics for STAT5, p38 MAPK, SAPK/JNK, Erk1/2, and Akt1 rela-
tive to WT neutrophils at early time points (up to 1 h; Fig. 5 B).
However, while the phosphorylation of STAT5 then declined in
WT neutrophils, CIS−/− neutrophils had prolonged expression of
STAT5 activation at later time points (2 h after stimulation; Fig. 5 B).
Extended JAK2-STAT5 activation was also observed in GM-
CSF–primed CIS−/− neutrophils after cytokine withdrawal
(Fig. 5 C). In contrast, the kinetics of STAT3 and Akt dephos-
phorylation were similar between WT and CIS−/− neutrophils
(Fig. 5 C). Consistent with extended JAK2-STAT5 activation in
the absence of CIS, we also observed prolonged activation of
p38 MAPK and SAPK/JNK (Fig. S3 C).
Figure 2. NK cells are involved in the per-
sistence of STIA. (A–E) STIA was induced by K/
BxN serum injection in (A) NK-deficient Mcl1fl/fl:
Ncr1-Cre mice or NK-sufficient Mcl1fl/fl mice (n =
18 mice pooled from three independent experi-
ments, SEM), (B) NK-deficient (anti-NK1.1–treated)
or NK-sufficient (isotype-treated; n = 12 mice
pooled from two independent experiments,
SEM), (C) WT or CD45−/− (intact population but
functionally deficient NK cells (n = 6 mice from
one experiment, SEM), (D) WT or GM-CSF−/− (n =
12 mice pooled from two independent experi-
ments, SEM), and (E) WT or IFN-γ−/− (n = 6 mice
from one experiment, SEM). Arthritis develop-
ment was monitored daily, and FACS-based quan-
tification of joint cell infiltrates (NK cells,
neutrophils, and macrophages) was performed
at the end of the experiment. p.i., post-injection.
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
Louis et al. Journal of Experimental Medicine 5 of 19
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SOCS proteins negatively regulate cytokine signaling
through direct inhibition, or proteasome-mediated degradation
of signaling components (Morris et al., 2018). Basal expression of
cell surface GM-CSFRβ was comparable in BM neutrophils from
50:50 WT:CIS−/− chimera mice (Fig. 5 D). However, following
exposure to GM-CSF in vitro, CIS−/− neutrophils had higher cell
surface GM-CSFRβ expression compared with WT cells. There
was no such difference in G-CSF–stimulated cells (Fig. 5 D). In
silico analysis using surface plasmon resonance of motifs in the
ligand binding α chain of the GM-CSFR did not reveal obvious
targets for CIS, but we identified a potential CIS binding site
corresponding to the amino acid sequence around the pTyr 822
residue of mouse GM-CSFRβ, and the pTyr 882 residue of human
GM-CSFRβ. The predicted binding affinity at this putative in-
teraction site is ∼1 µM, which could potentially allow CIS to
contribute to ubiquitination-mediated receptor turnover (Fig. 5 E).
CIS may therefore act as a negative regulator of GM-CSF sig-
naling in myeloid cells via proteasome-mediated degradation of
GM-CSFRβ.
CIS-deficient neutrophils display extensive changes in
response to GM-CSF
To examine the consequences of exaggerated GM-CSF signaling
in the absence of CIS, we performed 75-bp single-ended RNA
sequencing with simultaneous global proteomic validation on
WT and CIS−/− neutrophils, purified directly from murine BM
(unstimulated), or following culture with GM-CSF. Very few
differentially expressed genes were observed in unstimulated
CIS−/− neutrophils compared with WT (Fig. S4 A). Similarly,
there was little difference in gene expression following GM-CSF
stimulation for 4 h (Fig. S4 B), consistent with the delayed ki-
netics of CIS induction. However, CIS−/− neutrophils displayed
Figure 3. GM-CSF deletion in NK cells alleviates STIA and
CIA. (A) Schematic representation of Csf2fl/fl mice with loxP sites
flanking exon 3–4 for conditional deletion of Csf2 (GM-CSF)
upon crossing with mice carrying specific Cre recombinase un-
der promoter of interest. (B) GM-CSF and IFN-γ analyzed by
ELISA in culture supernatant of purified splenic NK cells from
Csf2fl/fl, Csf2fl/+:Ncr1-Cre and Csf2fl/fl:Ncr1-Cre mice following
stimulation with IL-15 and IL-18 (n = 6 mice pooled from two
independent experiments, SEM). (C) STIA development and
FACS-based quantification of joint cell infiltrates in Csf2fl/fl and
Csf2fl/fl:Ncr1-Cre mice (n = 12mice pooled from two independent
experiments, SEM). (D) Representative intracellular GM-CSF
staining of NK cells in the joints of Csf2fl/fl and Csf2fl/fl:Ncr1-Cre
mice upon STIA induction as in C. (E) Development of CIA and
FACS-based quantification of joint cell infiltrates in Csf2fl/fl and
Csf2fl/fl:Ncr1-Cre (n = 18 mice from one experiment, SEM). *, P <
0.05; **, P < 0.01; ***, P < 0.001.
Louis et al. Journal of Experimental Medicine 6 of 19
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extensive transcriptional changes 24 h after GM-CSF stimulation
(Fig. S4 C). The highest up-regulated transcripts included those
for chemokines, such as Cxcl3, Cxcl2, Ccrl2, Ccl4, and Pecam1, and
those associated with inflammatory effector functions, such as
Spp1, Edn1, Il1a, Ptgs2, Clec4n, Il1b, Plaur, and Il1f9 (Fig. 6 A). Global
proteomic analysis elucidated additional mechanisms by which
CIS deficiency might endow neutrophils with an enhanced pro-
inflammatory phenotype in response to GM-CSF (Fig. 6 B). CIS-
deficient neutrophils also demonstrated down-regulated protein
expression, including matrix metalloprotease 8 (MMP8) and
CYP4F3 (leukotriene B4/LTB4 omega-hydroxylase 2). Loss of
MMP8 has been associated with exacerbation of arthritis due to
its role in regulating neutrophil apoptosis (Cox et al., 2010;
Garćıa et al., 2010). CYP4F3, also known as leukotriene B4/
LTB4 omega-hydroxylase 2, also negatively regulates inflam-
mation by catalyzing the inactivation of LTB4 (Bramwell et al.,
2014, 2015; Chou et al., 2010; Christmas et al., 1999). Taken
together, these findings highlight CIS as a negative regulator of
GM-CSF–mediated neutrophil effector cell functions.
GM-CSF exerts various effects on myeloid cells, including
promoting survival and priming an inflammatory phenotype
(Croxford et al., 2015; Wicks and Roberts, 2016). To examine
whether CIS−/− neutrophils exhibit a GM-CSF–dependent sur-
vival advantage, we examined survival-related proteins in WT
and CIS−/− mice BM neutrophils following cytokine priming and
withdrawal. Both WT and CIS−/− neutrophils had rapid induc-
tion of cleaved caspase-3 upon G-CSF withdrawal (Fig. S5 A). In
contrast, GM-CSF withdrawal resulted in delayed induction of
cleaved caspase-3 in CIS−/− relative to WT neutrophils (Fig. S5 A),
consistent with enhanced bioactivity of GM-CSF on target cells.
In keeping with published literature, GM-CSF selectively in-
duced the pro-survival protein A1/Bfl-1 (Vier et al., 2016), and
its level was sustained for a longer period in CIS−/− neutrophils
upon GM-CSF withdrawal (Fig. S5 A). There was no difference
in the expression of prosurvival Mcl-1 protein in WT and CIS−/−
neutrophils, regardless of G-CSF or GM-CSF preconditioning
(Fig. S5 A).
RNA sequencing (RNASeq) data also revealed an enhanced
chemokine response in CIS−/− neutrophils (Fig. 6 A). CIS−/−
neutrophils secreted higher levels of CXCL2 and CCL3
chemokines upon GM-CSF stimulation (Fig. S5 B). Moreover,
CIS−/− neutrophils displayed enhanced cell surface CCRL2 ex-
pression following GM-CSF, but not G-CSF, stimulation (Fig.
S5, C and D). These chemokine responses promote tissue in-
flammation (Chou et al., 2010; Del Prete et al., 2017; Jacobs et al.,
2010). Thus, CIS deficiency confers extended GM-CSF signaling
that endows neutrophils with a prolonged lifespan and exag-
gerated, proinflammatory chemokine responses. Collectively,
these enhanced neutrophil responses to GM-CSF help explain
the cellular basis for exacerbated tissue inflammation in the
absence of CIS.
GM-CSF induces the differentiation of monocytes into CD11c+
macrophages (GM-Macs; Helft et al., 2015) and the production of
CCL17 and CCL22 by monocytes (Achuthan et al., 2016; Croxford
et al., 2015). Consistent with enhanced GM-CSF signaling, CIS-
deficient monocytes underwent accelerated differentiation into
GM-Macs in response to GM-CSF, relative to WT monocytes
(Fig. S5 E). Moreover, CIS−/− monocytes produced higher levels
of chemokines following GM-CSF stimulation (Fig. S5 F). Thus,
prolonged GM-CSF signaling in the absence of CIS also resulted
in exaggerated GM-CSF–driven responses in monocytes, which
would also worsen GM-CSF–driven inflammation.
IL-3 and IL-5 also signal through the common β chain and can
induce Cish expression in common myeloid progenitors and
eosinophils, respectively (Burnham et al., 2013; Matsumoto
et al., 1997; Yoshimura et al., 1995). Therefore, CIS deficiency
should confer exaggerated cellular responses to these cytokines.
Indeed, CIS−/− BM cells generated greater numbers of common
myeloid progenitors in response to IL-3 (Fig. S5 G), and of eo-
sinophils in response to IL-5 (Fig. S5 H).
Taken together, these data demonstrate that in the absence of
CIS, GM-CSF signaling is unrestrained and leads to enhanced
GM-CSF–dependent responses in myeloid cells, such as up-
regulation of proinflammatory chemokines by neutrophils and
Figure 4. IL-18 controls GM-CSF production by synovial NK cells. STIA
was induced by K/BxN serum injection in WT or IL-18−/− mice. (A) ELISA of
arthritic (STIA) and naive SF from WT mice (n = 8 mice pooled from two
independent experiments, SEM). (B and C) Arthritis development and (C)
FACS-based quantification of joint cell infiltrates in WT or IL-18−/− mice (n =
18 mice pooled from three independent experiments, SEM). Macs, macro-
phages. (D) Intracellular GM-CSF staining of NK cells in the arthritic joints
of WT or IL-18−/− mice as in B and C. (E) ELISA of arthritic SF from WT and
IL-18−/− mice (n = 8 mice pooled from two independent experiments, SEM).
*, P < 0.05; **, P < 0.01.
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monocyte-derived macrophages, which may translate to inten-
sified, GM-CSF–driven inflammation in vivo.
CIS−/−mice develop exacerbated GM-CSF–driven inflammation
Given these cellular and biochemical data, we directly investi-
gated the effect of CIS deficiency in the STIA model. CIS−/− mice
developed clinically exacerbated STIA compared with WT mice
(Fig. 7 A), which was confirmed by in vivo imaging for myelo-
peroxidase activity (Fig. 7 B). Lavage of inflamed joints showed
CIS−/− mice had comparable levels of GM-CSF and TNF, but
higher levels of pro-inflammatory cytokines and chemokines,
including IL-1β, LTβ4, CXCL2, CCL3, and CCL17 (Fig. 7 C). Of
note, increased levels of these proinflammatory mediators in
the arthritic joints of CIS−/− mice parallel the exaggerated
chemokine responses of GM-CSF–exposed neutrophils seen on
RNASeq (Fig. 6 A), and reduced expression of negative regu-
lators of inflammation, as revealed by proteomics (Fig. 6 B).
Exaggerated arthritis in the CIS−/− mice during STIA may
stem from dysregulated GM-CSF responses in neutrophils and/
or inflammatory monocytes, because these myeloid cells pre-
dominate in the inflamed joints and express the GM-CSFR.
However, Ly6C+ inflammatory monocytes are redundant in
STIA because CCR2−/− mice (which lack these Ly6C+ inflam-
matory monocytes) can still develop fulminant STIA (Misharin
et al., 2014). Thus, GM-CSF signaling, even in the absence of
Ly6C+ inflammatory monocytes, can support arthritis. To de-
termine whether GM-CSF signaling in neutrophils is indeed
responsible in driving the persistence of STIA, we generated
Figure 5. GM-CSF induces CIS to limit JAK2-STAT5 signaling in myeloid cells. (A) Expression of mRNA for SOCS proteins (Cish, Socs1, Socs2, and Socs3) by
WTmouse BM neutrophils analyzed by real-time PCR, normalized to Gapdh, at indicated times after stimulation with G-CSF or GM-CSF (n = 4 mice pooled from
two independent experiments, SEM). Data are expressed as fold induction relative to unstimulated neutrophils. (B) Immunoblot analysis of WT or CIS−/− BM
neutrophils stimulated in vitro with 100 ng/ml GM-CSF for indicated times. (C) Immunoblot analysis ofWT or CIS−/− BMneutrophils primed with GM-CSF for 3 h,
then washed, and cultured in cytokine-free media at various times post-wash. MFI, mean fluorescence intensity. (B and C) One experiment representative of
three independent experiments with similar results. (D) Flow-cytometric analysis of CD131 (GM-CSFRβ) surface expression on naive (t0) and G-CSF or GM-
CSF–stimulated BM neutrophils from WT:CIS−/− (50:50) chimeric mice (n = 4 mice pooled from two independent experiments, SEM). Data are expressed as
fold induction relative to unstimulated WT neutrophils. (E) Putative binding sites and affinity of CIS-SH2-BC to phosphopeptides corresponding to tyrosines
in the mouse and human GM-CSFRβ cytoplasmic domain. Data are from two experiments. *, P < 0.05.
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Csf2rbfl/fl:Mrp8-Cre mice to specifically delete GM-CSFRβ in
neutrophils (Fig. 7 D). Similar to GM-CSF−/−, NK-deficient mice
(anti-NK1.1-treated WT or Mcl1fl/fl:Ncr1-Cre), and Csf2fl/fl:Ncr1-
Cre mice, Csf2rbfl/fl:Mrp8-Cre mice had similar onset of arthritis
but did not maintain arthritis at later time points (Fig. 7 E). This
result suggests that GM-CSF signaling in neutrophils is specifi-
cally required for the persistence of STIA.
CIS deficiency also confers enhancedNK cell function, including
cytokine production (Delconte et al., 2016). We examined if am-
plified production of GM-CSF by CIS−/− NK cells might provide
another mechanism for enhanced joint inflammation. CIS−/− joint
NK cells, however, produced comparable levels of GM-CSF as de-
termined by intracellular FACS staining (Fig. 7 F), in keeping with
comparable levels in the joint lavage (Fig. 7 C). However, consistent
with NK cell and GM-CSF dependency, NK cell depletion or GM-
CSF neutralization alleviated STIA in CIS−/− mice (Fig. 7 G).
Finally, we also examined the effect of CIS deficiency in the
EAE model of central nervous system (CNS) inflammation.
Consistent with previous reports that EAE is driven by en-
cephalitogenic CD4 T cell–derived GM-CSF (Croxford et al., 2015;
Komuczki et al., 2019), GM-CSF deletion by tamoxifen admin-
istration in Csf2fl/fl:R26CreERT2 mice inhibited the progression
of EAE (Fig. S5 I). Intracellular cytokine staining confirmed GM-
CSF deletion but comparable IL-17A production in Csf2fl/fl:
R26CreERT2mice relative to littermate control Csf2fl/fl mice (Fig.
S5 J), consistent with a redundant role for IL-17A in driving EAE
(Haak et al., 2009). Similar to the STIA model of inflammatory
joint disease, CIS−/− mice developed exacerbated EAE (Fig. S5 K).
This effect was not due to an up-regulation of cytokine pro-
duction by CNS-infiltrating CD4 T cells (Fig. S5 L). Taken to-
gether, these results demonstrate a role for CIS as an inducible
regulator of GM-CSFR signaling in myeloid cells that normally
functions to limit tissue inflammation and immunopathology.
Discussion
In this study, we report two separate findings regarding GM-CSF
regulation during autoantibody-mediated inflammatory arthri-
tis. First, we show that GM-CSF is produced by synovial NK cells,
and these cells contribute to the persistence of inflammatory
arthritis. This is dependent on IL-18. Second, we reveal that GM-
CSF signaling in joint- and CNS-infiltrating myeloid cells is
negatively regulated by the inducible signaling suppressor CIS,
validating CIS as an endogenous brake on GM-CSF–driven tissue
inflammation.
The role of GM-CSF has been evaluated in the T cell–
dependent SKG and EAE models of inflammatory arthritis and
MS, respectively (Croxford et al., 2015; Hirota et al., 2018;
Komuczki et al., 2019). Although a genetic association with RA
has been described for the CSF2 locus (Okada et al., 2012), it is
unclear how GM-CSF contributes to the effector phase of tissue
inflammation mediated by autoantibodies in RA. Using a
T cell–independent, autoantibody-mediated arthritis model
(STIA) in Gr/fr mice, we identified NK cells as the main pro-
ducers of GM-CSF. NK cells are usually associated with pro-
duction of IFN-γ (Souza-Fonseca-Guimaraes et al., 2012; Zitti
and Bryceson, 2018), and IFN-γ–producing, CD56bright NK cells
are enriched in human RA synovium (Dalbeth and Callan, 2002;
Yamin et al., 2019). Although these studies suggest IFN-γ as a
key inflammatory mediator of arthritis, evidence for NK cell–
derived IFN-γ as a direct contributor to inflammatory arthritis
remains controversial in murine models (Lo et al., 2008;
Söderström et al., 2010). Here, we show that the cytokine-
producing function of NK cells, specifically GM-CSF rather
that IFN-γ, is essential for sustaining autoantibody-driven joint
inflammation in STIA. Genetic or pharmacologic depletion of
NK cells, or abrogation of GM-CSF production by NK cells, did
not prevent the early phase of inflammatory arthritis, but rather,
it reduced the accumulation of an inflammatory cell infiltrate
and the progression of inflammatory joint disease. GM-
CSF–producing NK cells were also found in human inflamma-
tory arthritis SF. GM-CSF production has been reported from
both human and mouse NK cells (Cuturi et al., 1989; Ho et al.,
Figure 6. CIS-deficient neutrophils display extensive transcriptional
and proteomic changes in response to GM-CSF. (A) Quantitative RNA
transcript analysis (vertical axis, reads per kilobase of exon per million reads)
of purified WT and CIS−/− BM neutrophils was performed by RNASeq fol-
lowing GM-CSF stimulation for 24 h. Selected genes that were differentially
expressed in CIS−/− neutrophils are shown (n = 3 biological replicates).
(B) Volcano plots representing the log2 protein ratios of differentially regu-
lated proteins in CIS−/− relative to WT neutrophils following quantitative
analysis. Proteins with a −log10 P > 1.3 and fold change >1 were deemed
differentially expressed and are highlighted in orange (n = 3 biological
replicates).
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2002), but there is little information about the functional im-
portance of NK cell–derived GM-CSF in a pathological context.
Our results support the notion that GM-CSF–producing NK cells
are an important component of an inflammatory cellular cascade
that maintains antibody-mediated inflammatory arthritis.
It has beenwell substantiated that the cytokines TNF and IL-1,
the alternative complement pathway, and innate immune cells
such as neutrophils, monocytes, and macrophages are key
players in the effector phase of STIA (Chou et al., 2010; Ji et al.,
2002a, b; Misharin et al., 2014; Sadik et al., 2012; Wipke and
Allen, 2001; Wipke et al., 2004). Human RA fibroblast-like
synoviocytes can also produce GM-CSF in response to IL-1 and
TNF (Alvaro-Gracia et al., 1991). However, using the Gr/fr
system, we found that the majority of GM-CSF–producing cells
during STIA are leukocytes and, more specifically, NK cells.
Thus, while nonleukocytes (e.g., stromal cells and fibroblast-
like synoviocytes) can produce GM-CSF, NK cell production
seems more important in maintaining autoantibody-mediated
arthritis. Furthermore, we found that the IL-1 family member
IL-18 activates synovial NK cells to produce GM-CSF during
STIA. RA synovial macrophages are known sources of IL-18,
and exogenous IL-18 can promote the secretion of GM-CSF
(along with nitric oxide, TNF, and IFN-γ) in synovial cell
cultures (Gracie et al., 1999). Unlike IL-1–deficient mice,
which cannot initiate STIA (Ji et al., 2002b), IL-18–deficient
mice developed inflammatory arthritis, but this did not pro-
gress. This phenotype resembles that seen in GM-CSF– and
NK-deficient mice. Thus, while IL-1 directly triggers the onset
Figure 7. CIS-deficient mice develop exacerbated STIA due to deregulated GM-CSF activation in neutrophils. (A) Arthritis development of WT and
CIS−/− mice (n = 12 mice pooled from two independent experiments, SEM). (B) Bioluminescence imaging of myeloperoxidase activity in the arthritic joints of
WT and CIS−/− mice, quantified as average radiance (n = 8 mice pooled from two independent experiments, SEM). (C) Pro-inflammatory mediators (GM-CSF,
TNF, IL-1β, LTB4, CXCL2, CCL3, and CCL17) analyzed by ELISA in SF of arthritic WT and CIS−/− mice (n = 8 mice pooled from two independent experiments,
SEM). (D) Representative CD131 (GM-CSFRβ) expression in blood neutrophils and monocytes of Csf2rbfl/fl and Csf2rbfl/fl:Mrp8-Cre mice (n = 6 mice from one
experiment). (E) Arthritis development in Csf2rbfl/fl and Csf2rbfl/fl:Mrp8-Cre mice (n = 6 mice from one experiment, SEM). (F) Intracellular GM-CSF staining of
NK cells in the joints of WT and CIS−/− mice during STIA (n = 8 mice pooled from two independent experiments, SEM). (G) Arthritis development in WT and
CIS−/− mice (treated with isotype, anti-NK1.1 or anti-GM-CSF mAbs; n = 12 mice pooled from two independent experiments, SEM). **, P < 0.01; ***, P < 0.001.
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of arthritis, IL-18 acts indirectly in STIA, by activating NK
cells to secrete GM-CSF.
IL-18 has been linked to NK activation in antiviral responses
(Madera and Sun, 2015; Mantovani et al., 2019). It has also been
implicated in autoimmune inflammation, through adjuvant ac-
tivity on T cells (Gracie et al., 1999; Lalor et al., 2011). It is
tempting to speculate that immune complexes could be impli-
cated in the production or release of IL-18. Alternatively,
damage-associated molecular patterns released by stressed cells
in the inflamed joint during STIA could in turn activate TLR
signaling and IL-18–activating inflammasomes in synovial
macrophages. Both IL-1β and IL-18 can be induced by TLR4 or
TLR7 ligands, but IL-18 production is sustained after activation,
while IL-1β up-regulation is transient (Zhu and Kanneganti,
2017). Potentially relevant ligands for TLR4 in arthritis include
aberrant extracellular high mobility group box chromosomal
protein 1 (HMGB1; Ostberg et al., 2010), citrullinated fibrinogen
(Sokolove et al., 2011), and alarmins S100A8 and S100A9 (van
Lent et al., 2008; van Lent et al., 2010). TLR7 ligands in RA SF
have also been described such as single strand RNA, microRNA
let-7b (miR-let-7b), or miR-let-7b–containing exosomes
(Chamberlain et al., 2013; Kim et al., 2016). Similar to the re-
duced arthritis in IL-18–, NK cell–, and GM-CSF–deficient mice
shown in this study, TLR-deficient mice (TLR4−/− and TLR7−/−)
can develop STIA, but with reduced severity (Choe et al., 2003;
Duffau et al., 2015). Thus, we propose an immune cascade in
which NK-derived GM-CSF contributes to the persistence of
autoantibody-driven arthritis. However, we do not exclude
contributions from GM-CSF–producing T cells, other ILC sub-
sets, and nonlymphoid stromal cells to the various stages of acute
and chronic inflammation in RA (Al-Mossawi et al., 2017; Hirota
et al., 2018; Reynolds et al., 2016). Rather, we suggest GM-
CSF–producing joint NK cells may play a key role in maintain-
ing tissue inflammation, in addition to GM-CSF from other
sources, produced at other times.
GM-CSF drives pathogenic inflammation in autoimmune
disorders such as RA and MS, and its signaling therefore needs
to be terminated after activation. Various SOCS family members
have been suggested to be induced by and therefore control GM-
CSF signaling (Bunda et al., 2013; Esashi et al., 2008; Jackson
et al., 2004). Here, we have provided physiological evidence
that CIS is a bona fide inhibitor of GM-CSF signaling, in a classic
negative feedback manner. In agreement with earlier reports
(Matsumoto et al., 1997; Yoshimura et al., 1995), CIS deletion
resulted in the prolonged activity of JAK2-STAT5–dependent
pathways, with a corresponding increase in GM-CSF–driven
effects on neutrophil survival, macrophage differentiation, and
chemokine production. Our in silico analysis further identified
cytoplasmic tyrosine motifs in the GM-CSFRβ subunit that in-
teract with CIS, which may allow CIS to induce receptor turnover
through ubiquitination and proteasome-mediated degradation.
Consistent with this prediction, we found elevated GM-CSFRβ
expression in CIS-deficient neutrophils following GM-CSF stim-
ulation. CIS deficiency also enhanced the biological effects from
IL-3 and IL-5, the receptors for which share the βc chain. These
findings strongly suggest that CIS targets the βc chain in this cy-
tokine receptor family for proteasome-mediated turnover.
In keeping with the relative absence of circulating GM-CSF in
healthy mice, CIS-deficient mice show no basal pathology or
alteration in myeloid cell frequencies in hematopoietic com-
partments (Stanley et al., 1994), but developed exacerbated GM-
CSF–dependent arthritis. GM-CSF–dependent tissue pathology
may be mediated by discrete GM-CSF–responding myeloid cell
types (Becher et al., 2016), such as Ly6C+ inflammatory mono-
cytes in the EAE model (Croxford et al., 2015) and eosinophils in
the chronic colitis model (Griseri et al., 2015). Here, we confirm
that neutrophils are key GM-CSF responders in the STIA setting,
because specific deletion of GM-CSFRβ in neutrophils alleviated
arthritis. Thus, the exacerbation of arthritis in CIS-deficient
mice likely stems from the prolonged activity of JAK2-
STAT5–dependent pathways and phenotypic changes in neu-
trophils following GM-CSF exposure in the inflamed joint
microenvironment. Transcriptomic and secreted protein analy-
ses of GM-CSF–primed CIS-deficient neutrophils revealed
marked up-regulation of pro-inflammatory chemokines associ-
ated with arthritis, including CXCL2 and CCL3 (Chou et al., 2010;
Jacobs et al., 2010). Additionally, proteomic analysis of GM-
CSF–primed CIS-deficient neutrophils revealed down-regulation
of key enzymatic brakes of inflammation, such as MMP8 and
CYP4F3, relative to WT neutrophils. Importantly, MMP8 has been
shown to control neutrophil apoptosis and resolution of arthritis
(Cox et al., 2010; Garćıa et al., 2010), while CYP4F3 catalyzes the
inactivation of pro-inflammatory LTB4 (Bramwell et al., 2014,
2015; Chou et al., 2010; Christmas et al., 1999). Reductions in these
anti-inflammatory pathways in GM-CSF–primed CIS-deficient
neutrophils are likely to have contributed to the exacerbation of
STIA in CIS-deficient mice because joint LTB4 levels were ele-
vated. Finally, we confirmed a role for CIS in inhibiting the
pathogenic function of GM-CSF in EAE. CIS-deficient mice de-
veloped exacerbated EAE, but this was not due to alterations in
GM-CSF or IL-17 production by CNS infiltrating CD4 T cells.
These data raise the possibility of several novel therapeutic
strategies for RA, along with the anti–GM-CSF therapies that are
already underway in clinical trials. First, modulating the func-
tion of NK cells through their activating and/or inhibitory re-
ceptors may impact on persistent tissue inflammation. Of note,
activation of NK cells by blocking the inhibitory CD94/NKG2A
receptor was shown to promote killing of pathogenic T follicular
helper and Th17 cells and alleviated autoimmune responses in
the CIA model (Leavenworth et al., 2011). Second, IL-18 inhibi-
tion may be a therapeutic possibility in RA. Such a rationale is
supported by our data showing a role for IL-18 in promoting the
GM-CSF–producing function of NK cells during inflammatory
arthritis. Earlier evidence showed the ability of IL-18 to prime
CIA (Gracie et al., 1999) and conversely, the alleviation of CIA
following treatment with anti–IL-18 antibodies, or using its en-
dogenous inhibitor IL-18–binding protein (Plater-Zyberk et al.,
2001). Finally, CIS mimetics could be designed to raise intra-
cellular stores of CIS in inflammatory cells and thereby suppress
GM-CSF–driven inflammation. Given our findings on the role of
CIS in regulating other cytokines that signal through the βc
chain, CIS mimetics may also limit the detrimental effects of IL-3
in sepsis (Weber et al., 2015) or of IL-5 in allergic inflammation
(Corren, 2011).
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Our findings may also have implications for CIS inhibitors to
increase JAK/STAT signaling in NK cells and CD8 T cells and
thereby enhance antitumor cytotoxicity (Delconte et al., 2016;
Palmer et al., 2015) and/or antitumor DC priming (Miah et al.,
2012). Inhibition of CIS in this context could potentially skew
tumor-resident myeloid/dendritic cell development and differ-
entiation, which may impact on tumor antigen presentation and
myeloid-derived suppressor cell differentiation. While such ef-
fects could be beneficial for treatment of the tumor, our findings
suggest a note of caution with regard to possible exacerbation of
any underlying autoantibody-mediated inflammatory disease.
In conclusion, we provide evidence that NK cells amplify
joint inflammation in autoantibody-induced inflammatory ar-
thritis by producing GM-CSF and that CIS is a physiological
inhibitor of GM-CSF signaling, acting to restrain the inflam-
matory properties of myeloid cells. These data significantly ex-
tend our appreciation of regulatory networks between IL-18,
GM-CSF, and NK cells, and suggest an underappreciated role for
recruited NK cells in driving sterile inflammatory diseases.
Materials and methods
Mice
The following mouse strains were used: C57BL/6J, Ncr1-Cre
(Narni-Mancinelli et al., 2011), CD45−/− (Huntington et al., 2005),
Mcl1fl/fl:Ncr1-Cre (Sathe et al., 2014), GM-CSF−/− (Stanley et al.,
1994), IFN-γ−/− (Dalton et al., 1993), IL-18−/− (Takeda et al., 1998),
CIS−/− (Palmer et al., 2015), Csf2rbfl/fl (Croxford et al., 2015), and
Mrp8-Cre (Passegué et al., 2004). Csf2fl/fl:Rosa26CreERT2, Csf2fl/fl:
Ncr1-Cre and Csf2rbfl/fl:Mrp8-Cre mice were generated by crossing
the strains described above. Gr/fr mice were generated by B. Ciric.
All genetically modified mouse strains in this study were on the
C57BL/6J background, bred andmaintained at TheWalter and Eliza
Hall Institute. Both male and female mice at 8–12 wk of age were
used for all experiments. Where appropriate and indicated, litter-
mate controls were used. No biological replicate was excluded
based on preestablished criteria. Cohort sizes are described in each
figure legend, with levels of statistical significance. All experiments
were approved by the Animal Ethics Committee of TheWalter and
Eliza Hall Institute.
Generation of Gr/fr mice
Gr/fr mice were generated by targeted integration, resulting in
replacement of the WT GM-CSF gene (Csf2) with vector. The
IRES-iCre-2A-BFP-SV40pA cassette was placed 25 bp after the
STOP codon in exon 4 in the 39 untranslated region of Csf2. The
flippase recombinase target (FRT)–flanked Neo cassette (FRT-
Neo-FRT) was placed 330 bp upstream of exon 4 in an intronic
sequence and was later excised through breeding with flippase
(FLP) transgenic mice. The short homology arm (SA) extends 2.1
kb 59 to the Neo cassette and the long homology arm (LA) 6.2 kb
39 to the IRES-iCre-2A-BFP-SV40pA cassette. Length in bps were
as follows: SA, 2,085; Neo, 1,561; MA [middle homology arm],
466; IRES-iCre-2A-BFP, 2,686; and LA, 6,620. The transgenic
construct has been designed to provide normal expression of
GM-CSF, driven by natural control elements of Csf2. GM-CSF
triggers the expression of iCre and BFP; given that BFP is
downstream of iCre, all BFP+ cells should also be iCre+. These
micewere then crossed Rosa26eYFP to enable lineage tracing via
iCre-mediated YFP expression.
Generation of GM-CSF flox mice
To generate Csf2fl/fl mice, a targeting vector was constructed at
the Gene Recombineering Facility (Monash University, Mel-
bourne, Australia), in which an FRT-PGK-neo-FRT-loxP cassette
was inserted downstream of exon 4, along with a loxP site in
intron 2. The vector was electroporated into C57BL/6J embry-
onic stem cells, and chimeric mice were generated from two
independent embryonic stem cell clones bearing the correctly
targeted locus. Heterozygous offspring were generated on a
C57BL/6J background, the PGK-neo sequence was removed by
intercrossing with transgenic mice ubiquitously expressing FLP
recombinase (Farley et al., 2000), and homozygous Csf2fl/fl mice
were produced by subsequent intercrosses. Genotyping was
performed using the primers 59-CACTTGGAACTGGGAACCTC-
39, 59-TTGATTTCACCTCCCTTTGG-39, and 59-CCGTAGACCCTG
CTGCAATA-39, which generate PCR DNA fragment sizes of 269
bp, 349 bp, and 193 bp for WT, targeted (PGK-neo deleted), and
post-cre recombined loci, respectively.
Human samples and primary cells
SF samples from RA patients of the Rheumatology Unit (Royal
Melbourne Hospital, Melbourne, Australia) were obtained at the
time of arthrocentesis (knee joints), and cellular fractions were
analyzed by flow cytometry. RA patients met the American
College of Rheumatology 2010 classification criteria and were
seropositive for rheumatoid factor and anti-citrullinated peptide
antibody. Samples from peripheral blood were taken from
healthy donors through the Volunteer Blood Donor Registry. All
samples used in this study were obtained under the approval of
the institutional review boards of The Walter and Eliza Hall
Institute and the Royal Melbourne Hospital. Written informed
consent was obtained from all participants.
STIA and antibody treatment
Pooled serum from 8–12-wk-old arthritic K/BxN mice
(Korganow et al., 1999; Monach et al., 2008) was transferred into
recipient mice (100 µl) i.p. on day 0. Clinical assessment for each
paw used the following scoring system: 0, no edema/erythema;
1, inflamed digits; 2, mild edema/erythema over one surface of
paw; 3, edema/erythema involving the entirety of paw; and 4,
edema/erythema involving the entirety of paw and joint anky-
losis. Scores were added for all four paws for a composite score.
Each experiment was performed two to five times to confirm
reproducibility. Whenever possible, scoring was performed in a
blinded manner. Mice were injected i.p. with anti-NK1.1 (clone
PK136, 200 μg/injection) to deplete NK cells or anti–GM-CSF
(clone MP1-22E9, 200 μg/injection) to neutralize GM-CSF. An-
tibody injections were given every 2 d starting on day 1, day 0
being the day of K/BxN serum injection.
CIA
CIA was induced by immunizing mice subcutaneously with type
II chicken collagen emulsified in CFA on days 0 and 14, as
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previously described (Inglis et al., 2008). Clinical assessment for
each paw used the following scoring system: 0, no edema/ery-
thema; 1, inflamed digits; 2, mild edema/erythema over one
surface of paw; 3, edema/erythema involving the entirety of
paw; and 4, edema/erythema involving the entirety of paw and
joint ankylosis. Scores were added for all four paws to generate a
composite score.
In vivo bioluminescence imaging of myeloperoxidase activity
On specified days, mice were injected i.p. with luminol
(200 mg/kg) and anaesthetized (isoflurane inhalation) before
bioluminescence imaging on an in vivo imaging systems spec-
trum instrument (Caliper; exposure time 180 s; binning 4, field
of view 12.5 cm). Regions of interest were manually selected
over front and rear paws using Living Image Software, and
identical regions of interest were used for time-course analysis.
C57BL/6J naive mice injected with luminol were used to control
for background luminescence (∼400 average radiance).
Induction of EAE and in vivo manipulation
Mice were immunized intradermally at the base of the tail with
200 µg MOG35–55 (Mimotopes) in CFA (BD), and 200 ng per-
tussis toxin (Sapphire Bioscience) in PBS was administered in-
traperitoneally on day 0 and day 2, as described previously
(Codarri et al., 2011). Clinical disease was monitored blinded to
group, as follows: 0, no detectable signs of EAE; 1, distal limp tail;
2, complete limp tail; 1.5, limp tail and hind limb weakness; 2,
unilateral partial hind limb paralysis; 2.5, bilateral partial hind
limb paralysis; 3, complete bilateral hind limb paralysis; and 4,
complete hind limb paralysis and unilateral forelimb paralysis.
To ablate GM-CSF–producing cells in Csf2fl/fl:Rosa26CreERT2
mice, tamoxifen was administered by oral gavage after onset in
experimental Csf2fl/fl:Rosa26CreERT2mice and littermate Csf2fl/fl
control animals.
Synovial joint lavage and immunophenotyping of cells from
the joints and CNS
Skin from the ankles and feet was removed, and inflamed soft
tissues 3 mm above the heel were dissected away from the tibia
and collected, along with arthritic joints. Digits were dis-
articulated without breaking bones to avoid contamination with
BM cells, soft tissues were cut into small pieces, and the tibio-
talar joint was opened posteriorly to expose the synovial lining.
To collect synovial/joint lavage, disarticulated paws (all four per
mouse) were incubated in 1 ml cold sterile PBS with agitation for
30 min at 4°C; cell-free supernatant was collected for ELISA.
Paw tissue was incubated in digestion buffer (2 mg/ml Colla-
genase IV, 1 mg/ml Dispase, and 0.5 mg/ml DNase I in PBS) for
30 min at 37°C, with agitation. For the EAE model, the brain and
spinal cord were digested with 2 mg/ml Collagenase IV, 1 mg/ml
Dispase, and 0.5 mg/ml DNase I in PBS for 30 min at 37°C with
agitation, followed by myelin removal using a continuous 28%
Percoll PLUS (GE) gradient for 30 min at 15,000 g at 4°C. Cells
released during digestion were filtered through 70-µm nylon
mesh, erythrocytes were lysed, and cells were stained with
viability dyes, incubated with FcBlock, and stained with
fluorochrome-conjugated antibodies (see Table S1 for antibodies,
clones, fluorochromes, and manufacturers). Quantification of
total cell numbers by flow cytometry was done using fluorescent
beads (Beckman Coulter). For intracellular staining of GM-CSF
ex vivo, joint cells were processed as described above, restimu-
lated with Cell Stimulation Cocktail Plus Protein Transport In-
hibitor for 4 h, then stained intracellularly with BD Cytofix/
Cytoperm and Perm/Wash solutions. Data were acquired on a BD
LSR Fortessa flow cytometer. Compensation and analysis of the
flow cytometry data were performed using FlowJo software
(Tree Star). “Fluorescence minus one” controls were used when
necessary to set gates.
Cell isolation for in vitro stimulation
For quantitative real-time PCR, immunoblotting, and in vitro
functional assays of myeloid cells (i.e., differentiation, survival,
or chemokine secretion), neutrophils were purified from BM of
C57BL/6J or CIS−/− mice by stepwise immunolabeling with bio-
tinylated anti-Ly6G (Biolegend), anti-biotin microbeads, and
positive selection with LS columns (Miltenyi Biotec). Subse-
quently, BM monocytes were isolated by stepwise immunolab-
eling with biotinylated anti-CD115 (Biolegend), anti-biotin
microbeads, and positive selection with LS columns (Miltenyi
Biotec). Cells of at least 95% purity were used for stimulation
with recombinant G-CSF or recombinant GM-CSF (100 ng/ml)
for indicated times.
NK cells frommouse spleen homogenates were enrichedwith
an NK cell isolation kit (Miltenyi Biotec) and sorted (PI– CD3–
CD19– TCRβ– F4/80– NK1.1+ NKp46+ CD49b+ CD49a–) on an ARIA
Fusion cell sorter (BD Biosciences) to achieve a final purity of
99–100%. NK cells were cultured at 37°C in RPMI 1640 medium
containing 10% FCS for 48 h. To assess cytokine production, NK
cells were stimulated with 10 ng/ml of rIL-15, 50 ng/ml of rIL-18,
and 50 pg/ml of rIL-12. At the endpoint, supernatant was re-
covered and IFN-γ and GM-CSF levels were measured by ELISA.
RNA isolation and quantitative real-time PCR
Total RNA was extracted from cells using an ISOLATE II RNA
Mini Kit (Bioline), digested with RNase-free DNase I (Bioline),
and reverse-transcribed into complementary DNA using Su-
perScript III reverse transcription (Invitrogen) and oligo(dT)
primers (Promega). Quantitative real-time PCR was performed
using Fast SYBR Green Master Mix (Thermo Fisher Scientific)
on a ViiA 7 PCR System (Thermo Fisher Scientific). Primers for
the genes assessed are shown in Table S1.
Immunoblotting
For immunoblotting, neutrophils from the BM were isolated by
positive-selection immunomagnetic enrichment using anti-
Ly6G biotin, followed by anti-biotin microbeads and an LS
column (Miltenyi Biotec). Monocytes were then isolated using
anti-CD115 biotin, anti-biotin microbeads, and LS columns.
The purity of enriched cells was consistently >95%. Cells were
stimulated in vitro with recombinant G-CSF (100 ng/ml) or
recombinant GM-CSF (100 ng/ml) for indicated times in RPMI
1640, supplemented with antibiotics and 10% heat-inactivated
FCS. In some experiments, cells were stimulated in the presence
of cytokine for 3 h and replenished with cytokine-free media for
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indicated times. Cells were washed in cold PBS and lysed in
radioimmunoprecipitation assay buffer in the presence of
protease and phosphatase inhibitors. Protein lysates were
normalized with a bicinchoninic acid protein assay and samples
loaded in SDS sample buffer. Protein extracts were separated
on NuPAGE 4–12% Bis-Tris Protein Gel and transferred to pol-
yvinylidene difluoride membranes. The membranes were
probed with antibodies and visualized with the Immobilon
Western Chemiluminescent HRP Substrate (see Table S1 for
antibodies, clones, and reagents).
Surface plasmon resonance
The binding of CIS protein to phosphopeptide motifs from the β
common receptorwas analyzed by competition experiments using
surface plasmon resonance. A biotinylated phosphotyrosine-
containing peptide from JAK3 was bound to a streptavidin de-
rivatized carboxymethyldextran chip (SAD 200 chip, Xantec)
using a flow-rate of 10 µl/min for 6 min at a concentration of
10 µg/ml in a Biacore 4000. A purified recombinant ternary
complex of CIS bound to elongin B and elongin Cwas then passed
over the surface of the chip at a concentration of 125 nM to assess
binding and measure the total response unit. This experiment
was then repeated with the β common receptor and GM-CSFRα
included as competitors to disrupt binding to the phosphopep-
tide on the surface of the chip. Each tyrosine-phosphorylated
peptide motif from the GM-CSFR was tested for competition at
concentrations of 10 µM to 41 µM (five serial threefold dilution of
10 µM). Binding was quantified by measuring the response units
for each injection and plotting the results as an IC50 (half-max-
imal inhibitory concentration) curve.
Sample preparation for mass spectrometry-based proteomics
BM neutrophils from BM of C57BL/6J or CIS−/− mice were sorted
(PI– CD3– CD19– CD115– CD11b+ Ly6G+) on a FACS ARIA Fusion
cell sorter (BD Biosciences) to achieve a final purity of 99–100%.
Neutrophils (3 × 106) from each genotype and stimulation con-
dition (n = 3/group) were washed three times with ice-cold PBS
before dry cell pellet storage at −80°C. Cells were lysed in pre-
heated (95°C) 5% SDS/10 mM Tris/10 mM Tris (2-carboxyethyl)
phosphine/5.5 mM and 2-chloracetamide and then heated at
95°C for 10 min. Neat trifluoracetic acid (Sigma) resulting in a
final concentration of 1% was added to hydrolyze DNA. Lysates
were quenched with 4 M Tris (pH 10) resulting in a final con-
centration of ∼140 mM (pH 7). Cell lysates (∼40 µg protein)
were transferred to a 2 ml LoBind Deep Well plate (Eppendorf)
and prepared for mass spectrometry analysis using the SP3
protocol, as described (Hughes et al., 2014), but with some
modifications. For all experiments withmagnetic beads, we used
a 1:1 combination mix of the two types of commercially available
paramagnetic carboxylate beads (Sera-Mag Speed beads, no.
45152105050250, no. 65152105050250, Thermo Fisher Scien-
tific). Beads were freshly prepared by rinsing with water three
times before use at a stock concentration of 20 µg/µl. Carbox-
ylate beads (4 µl) were added to all samples along with aceto-
nitrile (ACN, 70% final concentration vol/vol) and incubated at
room temperature for 18 min. Samples were then placed on a
magnetic 96-well rack (Ambion, Thermo Fisher Scientific),
supernatants were discarded, and the beads washed twice with
70% ethanol and once with neat ACN (180 µl washes). ACN was
completely evaporated from the tubes using a CentriVap (Lab-
conco) before the addition of 40 µl digestion buffer (10% tri-
fluoroethanol/100 mM NH4HCO3) containing Lys-C (Wako,
129–02541) and Trypsin-gold (Promega, V5280), each at a 1:25
enzyme:substrate ratio. Enzymatic digestions proceeded for
1.5 h at 37°C using the ThermoMixer C (Eppendorf), shaking at
400 rpm. Following digestion, samples were placed on a mag-
netic rack, the supernatants containing peptides were collected,
and an additional elution (50 µl) was performed using 2% DMSO
(Sigma) before sonication in a water bath for 1 min. The eluates
were pooled and transferred to the top of preequilibrated C18
StageTips (2× plugs of 3M Empore resin, no. 2215) for sample
cleanup. The eluates were lyophilized to dryness using a Cen-
triVap (Labconco), before reconstituting in 60 µl 0.1% FA/2%
ACN ready for mass spectometry analysis.
Mass spectrometry analysis
Peptides (2 µl) were separated by reverse-phase chromatogra-
phy on a C18 fused silica column (inner diameter 75 µm, OD
360 µm × 25 cm length, 1.6 µm C18 beads) packed into an emitter
tip (IonOpticks), using a nano-flow HPLC (M-class, Waters). The
HPLC was coupled to an Impact II UHR-QqTOF mass spec-
trometer (Bruker Daltonics, Bremen) using a CaptiveSpray
source and nanoBooster at 0.20 Bar using ACN. Peptides were
loaded directly onto the column at a constant flow rate of 400 nl/
min with buffer A (99.9% Milli-Q water, 0.1% FA) and eluted
with a 90-min linear gradient from 2 to 34% buffer B (99.9%
ACN, 0.1% FA). Mass spectra were acquired in a data-dependent
manner including an automatic switch between mass spec-
tometry and tandem mass spectrometry scans using a 1.5-s duty
cycle and 4 Hz mass spectometry 1 spectra rate followed by
tandem mass spectrometry scans at 8–20 Hz dependent on
precursor intensity for the remainder of the cycle. Mass spec-
tometry spectra were acquired between a mass range of 200 and
2,000 m/z. Peptide fragmentation was performed using
collision-induced dissociation. Raw files consisting of high-
resolution tandem mass spectrometry spectra from the Bruker
Impact II instrument were processed with MaxQuant (version
1.5.8.3) for feature detection and protein identification using
the Andromeda search engine (Cox et al., 2011). Extracted peak
lists were searched against the UniProtKB/Swiss-Prot Mus
musculus database (October 2016) and a separate reverse decoy
database to empirically assess the false discovery rate (FDR)
using strict trypsin specificity allowing up to two missed
cleavages. The minimum required peptide length was set to 7
amino acids. In the main search, precursor mass tolerance was
0.006 daltons, and fragment mass tolerance was 40 ppm. The
search included variable modifications of oxidation (methio-
nine), N-terminal acetylation, the addition of pyroglutamate (at
N termini of glutamate and glutamine), and a fixed modifica-
tion of carbamidomethyl (cysteine). The “match between runs”
option in MaxQuant was used to transfer identifications made
between runs on the basis of matching precursors with high
mass accuracy (Cox and Mann, 2008). Peptide-spectrum match
and protein identifications were filtered using a target-decoy
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approach at an FDR of 1%. Label-free quantification (LFQ)
quantification was selected, with a minimum ratio count of 2.
Peptide-spectrum match scores and protein identifications
were filtered using a target-decoy approach at a FDR of 1%. Only
unique and razor peptides were considered for quantification
with intensity values present in at least two out of three rep-
licates per group. Statistical analyses were performed using
LFQAnalyst (https://bioinformatics.erc.monash.edu/apps/
LFQ-Analyst/) whereby the LFQ intensity values were used
for protein quantification. Missing values were replaced by
values drawn from a normal distribution of 1.8 SDs and a width
of 0.3 for each sample (Perseus-type). Protein-wise linear
models combined with empirical Bayes statistics were used for
differential expression analysis using Bioconductor package
Limma, whereby the adjusted P value cutoff was set at 0.05 and
log2 fold change cutoff set at 1. The Benjamini–Hochberg
method of FDR correction was used.
RNASeq
BM neutrophils from BM of C57BL/6J or CIS−/− mice were sorted
(PI– CD3– CD19– CD115– CD11b+ Ly6G+) by a FACS ARIA Fusion
cell sorter (BD Biosciences) to achieve a final purity of 99–100%.
Neutrophils were stimulated with recombinant GM-CSF
(100 ng/ml) for indicated times. RNA from neutrophils was
extracted with an RNeasy Plus Mini Kit (QIAGEN), according to
the manufacturer’s protocol. Extracted RNA was quantified
using an Agilent 2200 TapeStation System (Agilent) with RNA
ScreenTapes (Agilent) or High Sensitivity RNA ScreenTapes
(Agilent). Next-generation sequencing libraries were created
with 100 ng of RNA from samples with distinct 18S and 28S
peaks and RNA Integrity Number values greater than 7, using
an NEBNext Ultra II Directional RNA Library Prep Kit for Il-
lumina New England Biolabs) according to the manufacturer’s
protocol. RNA libraries were pooled and sent for single-end
75 bp sequencing at the Genomics Laboratory (The Walter
and Eliza Hall Institute of Medical Research) on a NextSeq
500 next-generation sequencer (Illumina) to obtain ∼20 mil-
lion reads per sample.
Bioinformatics
Single-end 75-bp reads corresponding to WT and CIS−/− neu-
trophils treated with GM-CSF in 0 (unstimulated), 4 h and 24 h
time-points RNASeq samples were quality checked using fastqc
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc).
Low-quality base pairs were trimmed from the end of the reads
using Trimmomatic (Bolger et al., 2014). Reads were aligned to
mm10 using STAR (Dobin et al., 2013). Reads were summarized
at the gene level using featureCounts (Liao et al., 2014). The
differential expression and pathway enrichment analysis were
performed using edgeR (Chen et al., 2014) and limma (Ritchie
et al., 2015) R/Biocondutor packages. Differential protein
analysis was performed using the diffSplice function in limma.
Briefly, technical variabilities and batch effects in the LFQ
normalized peptide intensities from MaxQuant were estimated
from a surrogate variable analysis and incorporated into the
differential expression model. A protein is identified as dif-
ferentially expressed if the protein-wise P values derived from
the Simes-adjusted P values for its peptides is significant
(FDR 0.05).
Statistics
In arthritis experiments, differences in clinical score between the
groups were assessed using two-way ANOVA for repeated meas-
urements, with Bonferroni post-test correction to compare dif-
ferences between the groups. For other experiments, differences
between groups were determined using unpaired Student’s t tests,
as indicated. All analyses were performed using GraphPad Prism
version 7 (GraphPad Software). Data are shown as means ± SEM
unless stated otherwise. Levels of statistical significance are ex-
pressed as P values: *, P < 0.05, **, P < 0.01, and ***, P < 0.001.
Data and materials availability
The accession number for the RNASeq reported in this paper is
GEO accession no. GSE128909. The mass spectrometry proteo-
mics data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository (Vizcaı́no et al., 2016)
with the dataset identifier PXD012794.
Online Supplemental material
Fig. S1 shows the generation and validation of Gr/fr mice. Fig. S2
shows flow-cytometric analyses of GM-CSF in human NK cells
and T cell subsets from RA SF and peripheral blood of healthy
donors. Fig. S3 shows induction of CIS in humanmyeloid cells by
GM-CSF stimulation, the myeloid compartment of CIS−/− mice,
and prolonged p38 MAPK and SAPK/JNK signaling in CIS−/−
neutrophils in response to GM-CSF. Fig. S4 shows an overview
of the RNASeq analysis of WT and CIS−/− neutrophils at various
times after GM-CSF stimulation. Fig. S5 shows hyperactivation
of CIS−/− myeloid cells in response to GM-CSF and exacerbated
EAE in CIS−/− mice. Table S1 contains a list of reagents and
software used in this study.
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Passegué, E., E.F.Wagner, and I.L.Weissman. 2004. JunB deficiency leads to a
myeloproliferative disorder arising from hematopoietic stem cells. Cell.
119:431–443. https://doi.org/10.1016/j.cell.2004.10.010
Plater-Zyberk, C., L.A. Joosten, M.M. Helsen, P. Sattonnet-Roche, C. Sieg-
fried, S. Alouani, F.A. van De Loo, P. Graber, S. Aloni, R. Cirillo, et al.
2001. Therapeutic effect of neutralizing endogenous IL-18 activity in
the collagen-induced model of arthritis. J. Clin. Invest. 108:1825–1832.
https://doi.org/10.1172/JCI200112097
Pridgeon, C., G.P. Lennon, L. Pazmany, R.N. Thompson, S.E. Christmas, and
R.J. Moots. 2003. Natural killer cells in the synovial fluid of rheumatoid
arthritis patients exhibit a CD56bright,CD94bright,CD158negative
phenotype. Rheumatology (Oxford). 42:870–878. https://doi.org/10
.1093/rheumatology/keg240
Rauch, P.J., A. Chudnovskiy, C.S. Robbins, G.F. Weber, M. Etzrodt, I. Hil-
gendorf, E. Tiglao, J.L. Figueiredo, Y. Iwamoto, I. Theurl, et al. 2012.
Innate response activator B cells protect against microbial sepsis. Sci-
ence. 335:597–601. https://doi.org/10.1126/science.1215173
Reynolds, G., J.R. Gibbon, A.G. Pratt, M.J. Wood, D. Coady, G. Raftery, A.R.
Lorenzi, A. Gray, A. Filer, C.D. Buckley, et al. 2016. Synovial CD4+
T-cell-derived GM-CSF supports the differentiation of an inflammatory
dendritic cell population in rheumatoid arthritis. Ann. Rheum. Dis. 75:
899–907. https://doi.org/10.1136/annrheumdis-2014-206578
Ritchie, M.E., B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi, and G.K. Smyth.
2015. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. 43:e47. https://
doi.org/10.1093/nar/gkv007
Sadik, C.D., N.D. Kim, Y. Iwakura, and A.D. Luster. 2012. Neutrophils or-
chestrate their own recruitment in murine arthritis through C5aR and
FcγR signaling. Proc. Natl. Acad. Sci. USA. 109:E3177–E3185. https://doi
.org/10.1073/pnas.1213797109
Sathe, P., R.B. Delconte, F. Souza-Fonseca-Guimaraes, C. Seillet, M. Chopin,
C.J. Vandenberg, L.C. Rankin, L.A. Mielke, I. Vikstrom, T.B. Kolesnik,
et al. 2014. Innate immunodeficiency following genetic ablation of Mcl1
in natural killer cells. Nat. Commun. 5:4539. https://doi.org/10.1038/
ncomms5539
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Figure S1. Characterization of Gr/fr mice. (A) Gr/fr mice were generated by targeted integration, resulting in replacement of WT GM-CSF gene (Csf2) with
the vector. The IRES-iCre-2A-BFP-SV40pA cassette was placed 25 bp after the STOP codon in exon 4, in the 39 untranslated region (UTR) of the Csf2. The FRT-
flanked Neo cassette (FRT-Neo-FRT) was placed 330 bp upstream of exon 4 in intronic sequence and was later excised through breeding with FLP transgenic
mice. The SA extends 2.1 kb 59 to the Neo cassette and the LA 6.2 kb 39 to the IRES-iCre-2A-BFP-SV40pA cassette. Length in bps: SA, 2,085; Neo, 1,561; middle
homology arm (MA), 466; IRES-iCre-2A-BFP, 2,686; LA, 6,620. The transgenic construct has been designed to provide normal expression of GM-CSF, driven by
natural controlling elements of Csf2. GM-CSF induction triggers the expression of iCre and BFP, given that BFP is downstream of iCre, all BFP+ cells should also
be iCre+. These mice were then crossed Rosa26eYFP to enable lineage tracing via iCre-mediated YFP expression. (B) Naive CD4+ T cells were isolated
from Gr/fr mice mice and cultured in Th17 polarizing conditions and analyzed by flow cytometry comparing BFP reporter signal to intracellular staining of
GM-CSF. (C) Flow-cytometric analysis of GM-CSF–producing cells (BFP+ YFP+) in the lung of naive Gr/fr mice. (D) Flow-cytometric analysis of GM-
CSF–producing cells (BFP+ YFP+) in the joints of arthritic Gr/fr mice.
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Figure S2. Human NK cells produce GM-CSF in RA SF. (A and B) FACS (A) and bar plots (B) showing the relative frequency of NK cell subsets (immature
CD56bright and mature CD56dim) in PBMCs from healthy donors or RA SF. Vertical bars, mean ± SEM, n = 3 donors. (C) FACS plots showing intracellular GM-CSF
and IFN-γ staining of viable lineage– CD7+ cells in RA SF. (D and E) Ratio of NK (CD3+ NKp46+), CD4+ T cells (CD3+ CD4+) and CD8+ T cells (CD3+ CD8+)
populations among the GM-CSF+ cells (D) or among the GM-CSF+IFN-γ+ cells from RA SF cells as in C.
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Figure S3. Characterization of CIS-deficient myeloid cells. (A) Immunoblotting of pSTAT5, CIS, and β-actin in human blood neutrophils and monocytes
from healthy donors treated with GM-CSF. One experiment representative of three independent experiments with similar results. (B) Flow-cytometric analysis
of myeloid cell populations in the BM, blood, spleen, and peritoneal cavity of naive WT and CIS−/−mice (n = 6 mice from one experiment, SEM). (C) Immunoblot
analysis for pJAK2, pSTAT5, p-p38 MAPK, pSAPK/JNK, pErk1/2, CIS, and β-actin of WT or CIS−/− BM neutrophils primed with GM-CSF and washed free of
cytokine-containing media before lysis at various times after wash. One experiment representative of three independent experiments with similar results. cDC,
conventional dendritic cell.
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Figure S4. RNASeq analysis ofWT and CIS−/− neutrophils. (A–C)MD plots showing log-fold change (CIS−/− vs. WT) and average abundance of genes for the
corresponding RNASeq in BM neutrophils following isolation (A, unstimulated), or cultured in GM-CSF-containing media for 4 h (B) or 24 h (C). Significant
differentially expressed (absolute log2 FC ≥ 1, FDR ≤ 0.05) genes are colored red (up-regulated) or blue (down-regulated).
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Figure S5. CIS-deficiency confers hyperactivation of GM-CSF–driven responses inmyeloid cells in vitro and in EAE. (A) Immunoblot analysis for cleaved
caspase-3, A1/Bfl-1, Mcl-1, or β-actin of WT or CIS−/− BM neutrophils stimulated with GM-CSF and washed free of cytokine-containing media before lysis at
various times after wash. One experiment representative of three independent experiments with similar results. (B) CXCL2 and CCL3 analyzed by ELISA in
culture supernatant of BM neutrophils fromWT and CIS−/−mice following stimulation with GM-CSF for 24 h (n = 3 mice from one experiment, SEM). (C and D)
Flow-cytometric analysis of CCRL2 and CD11a surface expression on G-CSF or GM-CSF–stimulated BM neutrophils from WT or CIS−/− mice. (D) Data are
expressed as percentage of neutrophils (n = 3 mice from one experiment, SEM). (E) Frequency of CD11c+ GM-Macs in GM-CSF–stimulated BMmonocytes from
WT and CIS−/− mice at indicated times (n = 4 mice pooled from two independent experiments, SEM). (F) Expression of mRNA for GM-CSF–inducible che-
mokines (Ccl17 and Ccl22) by BM monocytes analyzed by real-time PCR, normalized to Gapdh, at 8 h after stimulation with GM-CSF (n = 3 mice from one
experiment, SEM). (G) Flow-cytometric analysis of WT and CIS−/− BM common myeloid progenitor cells upon culture in IL-3 for 3 d (n = 3 mice from one
experiment, SEM). (H) Flow-cytometric analysis of WT and CIS−/− BM eosinophils upon culture in IL-5 for 3 d (n = 3 mice from one experiment, SEM). (I) EAE
development in Csf2fl/fl and Csf2fl/fl:R26CreERT2 mice with tamoxifen treatment after EAE onset (n = 12 mice pooled from two independent experiments, SEM).
(J) Representative intracellular GM-CSF and IL-17A staining of CD4 T cells in the CNS of Csf2fl/fl and Csf2fl/fl:Ncr1-Cre mice with EAE following tamoxifen
treatment as in I. (K) EAE development in WT and CIS−/− mice (n = 12 mice pooled from two independent experiments, SEM). (L) Representative intracellular
GM-CSF and IL-17A staining of CD4 T cells in the CNS of WT and CIS−/− mice with EAE as in K. *, P < 0.05; **, P < 0.01.
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Table S1 is provided online and shows reagents.
Louis et al. Journal of Experimental Medicine S7






_20191421.pdf by guest on 02 June 2021
